Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBD-HPV: De-Intensification for HPV+ HNSCC
NCT04849377Phase 2Withdrawn
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Jun 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cisplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Icahn School of Medicine at Mount Sinai. Planned start Jun 2022; status: withdrawn.
02
Drugs
cisplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04849377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849377.